---
id: blinding
title: Blinding and Placebo Comparability
subtitle: Nine sources, five different blinding mechanisms, and a published admission of partial unblinding that never appears in the primary outcome paper
strength: strong
status: complete
last_updated: 2026-04-15
owner: blinding-track
topics:
  - blinding
  - trial-design
  - reporting-bias
---

## Thesis

The TLC trial documentary record contains **nine independent source documents** that discuss or should discuss the trial's blinding mechanism. These nine sources describe **five mutually incompatible mechanisms** (plus three silences), and on every point where two sources overlap, at least two contradict each other on a material fact. The scientific literature that the clinical community has relied on since 2001 reflects only one of these five mechanisms — the one that appears solely in the post-treatment revision of the protocol, with an amount (200 mg of succimer) that was not in the operative pre-randomization protocol. NIEHS anticipated the blinding problem in the pre-contract RFP Amendment, explicitly suggested a validation procedure (querying parents to check unblinding), and the trial's published literature never reports whether that validation was done.

The contradiction is not a minor drafting inconsistency. It is load-bearing for two reasons:

1. **Blinding is a core integrity element of a double-blind placebo-controlled RCT**, and the trial's primary outcome paper (Rogan et al. 2001 NEJM) asserts "double-blind" without describing how it was achieved.
2. **The only published papers that describe the mechanism** (TLC Group 2000 *Pediatric Research*; Dietrich et al. 2004 *Pediatrics*) also contain explicit admissions that the blinding was partial ("not the room-filling odor of succimer"; "the additional 14% likely because of the odor of the drug") — admissions that are absent from the primary outcome publication.

## Summary of findings (the punchline)

**Nine sources. Five mechanisms. Three silences. Zero sources describe the mechanism in a way that is consistent with every other source.** The sole description of the blinding method in the core scientific literature (the 2000 and 2004 papers) matches only one of four protocol-internal descriptions — the one from v10 §4.6, dated November 4, 1997, ten months after randomization ended. No source on the public record describes the mechanism that was operative during randomization (August 1994 – January 1997). The 1998 design paper and the 2001 NEJM primary outcome paper are silent on mechanism entirely. The RFP Amendment, written by NIEHS before the contract was awarded, explicitly warned that parental blinding was likely impossible and suggested a parental-guess validation that the published literature never reports having done.

## Source inventory

| # | Source | Date | Mechanism described | Amount | Match to other sources |
|---|--------|------|---------------------|--------|------------------------|
| 1 | NIEHS RFP Amendment 01 to NIH-ES-92-31 | **October 22, 1992** (pre-contract) | None specified; acknowledges unblinding risk; suggests parental-guess validation | — | anticipates but does not prescribe mechanism |
| 2 | Protocol v9, §4.6 (Maintenance of Double-blind) | Aug 23, 1994 (pre-randomization) | Plastic canister in **every bottle** (symmetric) | **100 mg** succimer | matches no other source |
| 3 | Protocol v9, §9.1.1 (Repackaging of Trial Medications) | Aug 23, 1994 | **Mucomyst-soaked filter paper** in placebo bottles only; unsoaked filter paper in succimer bottles | 2 cm² × 20% Mucomyst | matches no other source |
| 4 | Protocol v10, §4.6 | Nov 4, 1997 (post-treatment) | Plastic canister in **every bottle** (symmetric) | **200 mg** succimer | matches 2000 and 2004 papers |
| 5 | Protocol v10, §9.1.1 | Nov 4, 1997 | **Swapped canisters**: 200 mg active drug in placebo bottles; 200 mg placebo in succimer bottles | 200 mg each | matches no other source |
| 6 | TLC Trial Group 1998 (design and recruitment paper), *Paediatr Perinat Epidemiol* | 1998 | **Not described** (6 "blind" occurrences, all generic) | — | silent |
| 7 | TLC Trial Group 2000 (safety and efficacy paper), *Pediatric Research* | 2000 | Plastic canister in **every bottle** (symmetric) | **200 mg** succimer | matches v10 §4.6 only |
| 8 | Rogan et al. 2001 (primary outcome paper), *NEJM* | 2001 | **Not described** (1 "blind" occurrence, generic) | — | silent |
| 9 | Dietrich et al. 2004 (7-year follow-up), *Pediatrics* | 2004 | Plastic canister in **every bottle** (text substantially cut-pasted from 2000 paper) | **200 mg** succimer | matches v10 §4.6 and 2000 paper |
| — | Chen et al. 2005, *Pediatrics* | 2005 | **Not described** | — | silent |

**Randomization period:** Children enrolled and randomized **August 1994 – January 1997** (per TLC Trial Group 1998 design paper, Fig. 1, p. 326). The operative protocol during this entire period was the August 23, 1994 version (Protocol 9). **Protocol 10 is dated November 4, 1997, more than ten months after the last child was randomized and after all clinical treatment had concluded.**

**Key dates in sequence:**

- **October 8, 1992** — NIEHS preproposal conference
- **October 22, 1992** — RFP Amendment 01 issued (Source 1)
- **November 24, 1992** — proposals due
- **June 1993** — contract awards (approximate)
- **August 23, 1994** — Protocol v9 dated (Sources 2 and 3)
- **August 1994** — randomization begins
- **January 22, 1997** — randomization ends (last child enrolled)
- **June 2001** — last child completes 36-month follow-up
- **November 4, 1997** — Protocol v10 dated (Sources 4 and 5)
- **1998** — Design and recruitment paper published in *Paediatr Perinat Epidemiol* (Source 6)
- **2000** — Safety and efficacy paper published in *Pediatric Research* (Source 7)
- **May 10, 2001** — Primary outcome paper published in *NEJM* (Source 8)
- **2004** — 7-year follow-up paper published in *Pediatrics* (Source 9)
- **September 20, 2007** — RFP Amendment surfaces as court exhibit in Featherstone v. KKI
- **October 30, 2004** — Last Wayback Machine snapshot of NIEHS-hosted Protocol v10 HTML

---

## Source 1 — NIEHS RFP Amendment 01 to NIH-ES-92-31

**Provenance:** Amendment 01 to the original NIEHS RFP for what became the TLC trial contracts. Effective date stated in the document header: **October 22, 1992**. RFP number: **NIH-ES-92-31** ("Toxicity of Lead in Children — Clinical Centers"). The amendment memorializes the Q&A from the preproposal conference held at NIEHS on **October 8, 1992**, and was distributed to all potential offerors ahead of the November 24, 1992 proposal deadline. It pre-dates Protocol v9 (August 23, 1994) by more than a year and a half, and pre-dates the contract awards (mid-to-late June 1993) by eight months.

**How this document became public:** The RFP Amendment was not voluntarily made public by NIEHS. It was surfaced through litigation discovery in **Featherstone v. Kennedy Krieger Institute**, Case 1:07-cv-01120-WMN (D. Md.), where it was filed as **Exhibit D, Document 37-4**, on **September 20, 2007**. The full original RFP has not been located; only this amendment is available to the public.

**Repository paths:** `RFP Amendment of Contract.pdf` (repository root), `harm/RFP_Amendment.pdf`, `ideas/review_fully/RFP_Amendment.pdf`. Knowledge base entry: [[niehs-1992-rfp-amendment]].

### Verbatim text — BLINDING subsection

> **BLINDING**
>
> What justifies loss of blinding? What level of blinding is required?
>
> Offerors must propose what they believe to be the best study design. Designs consistent with the basic trial include fully blinded designs with an escape, in which the study physician, the parent and child, and the psychometrician are all blind, to single blind designs, in which treatment assignment is random and the psychometrician is blinded but the child's blood lead is managed openly. In general, the more open the design, the more likely it is that questions of bias will be raised about the results. Proposals that do not offer truly random treatment assignment and blind psychometric assessment are proposing in essence a different study than what was approved at NIEHS. The degree of blinding proposed by the offeror will be considered, among other things, in the evaluation of proposals, but the final decision will be made by the Steering Committee.
>
> **Can parents be made blind to treatment, if children given active drug smell like mercaptan?** Possibly not. Offerors could consider proposing to query parents about whether they knew if the child was getting active drug, and see if they get it right. **NIEHS knows of no agent that smells like a mercaptan and could serve as a placebo.**

### Verbatim text — related placebo/compliance passage

> Should compliance be monitored? The RFP said that putting an easily monitored substance, such as riboflavin, in the vitamin supplement could be done. **It will be technically more difficult to alter the succimer-placebo.** NIEHS believes that compliance is an issue, and a means to monitor it should be proposed.

### What this source establishes

1. **NIEHS knew, before any contract was awarded, that parental blinding might be impossible because of succimer's mercaptan smell.** This is an explicit, on-the-record pre-contract acknowledgment.
2. **NIEHS knew, before any contract was awarded, that no existing pharmaceutical agent existed that could credibly masquerade as a placebo for succimer.** *"NIEHS knows of no agent that smells like a mercaptan and could serve as a placebo."*
3. **NIEHS explicitly suggested a validation procedure:** query parents on whether they knew which arm their child was in, and see if they guessed correctly. **The published TLC literature never reports having performed this check**, or any other unblinding-validation procedure. Whether the investigators ran this test internally and the data were suppressed, or whether they simply never ran it, is a question that court discovery or internal records would have to answer.
4. **NIEHS made the degree of blinding a proposal evaluation criterion**, but left the specific mechanism to the offerors. The minimum requirement was "truly random treatment assignment and blind psychometric assessment." NIEHS contemplated that single-blind designs (where clinicians manage blood lead openly and only the psychometrician is blinded) would be acceptable, and that fully-blinded designs with an "escape" would also be acceptable. **The trial did not require full double-blinding as a matter of protocol integrity.**
5. **The compliance monitoring passage is an implicit admission that the succimer-placebo formulation was fixed and difficult to modify.** NIEHS noted that altering the vitamin supplement (by adding riboflavin) was easy but altering the placebo was "technically more difficult" — a framing consistent with a placebo that was already specified and hard to change.

### Why this matters for the re-examination

The RFP Amendment is direct, contemporaneous evidence that **the blinding problem was recognized by the funder before the trial was designed**. Any claim in the published literature that the trial was conducted as a "double-blind" RCT must be evaluated against this pre-contract acknowledgment that double-blinding was "possibly not" achievable in principle. The explicit NIEHS suggestion to query parents to check unblinding is an unusually direct roadmap for a validation procedure that would have, if performed and published, either confirmed or falsified the blinding claim. The absence of that validation in the published record is itself a finding.

---

## Source 2 — Protocol v9, §4.6 (Maintenance of Double-blind)

**Provenance:** Treatment of Lead-Exposed Children Trial Protocol, dated in the running footer as **8/23/94** (August 23, 1994). Source path header in the document: `d:\lead\protocol\protocol.v9`. This is the pre-randomization version of the protocol — the operative protocol during the August 1994 – January 1997 randomization period. The user has hand-transcribed this protocol into a digital RTF (see `/Users/danielschwartz/Desktop/untitled folder/Protocol_version_9.rtf`); the scanned original is at `tlc_references_pdfs/Protocol_v_9 .pdf` (note trailing space in filename). A parallel scan with a September 21, 1994 title page is a court-discovery artifact — the content pages in that version all bear the same 8/23/94 footer; the September cover sheet was added during litigation discovery, not as a new revision. **There is only one Protocol 9.**

### Verbatim text — §4.6 Maintenance of Double-blind

> **4.6. Maintenance of Double-blind**
>
> Treatment will be blinded to the fullest extent possible. Both parents and clinic personnel will be blinded to the child's PbB levels during treatment until six months after randomization.
>
> Succimer emits a strong odor of sulfur, while the placebo for succimer emits a smell of alcohol. Therefore, it will not be possible to provide a fully comparable placebo. However, to provide a more sulfur-like smell to the placebo, **a vented cylindrical plastic canister, 0.5 inches in diameter and 0.6 inches in length, will be filled with 100 mg. of succimer and added to all bottles of study drug (not just those containing succimer).** The addition of the canister will change the odor of the placebo to one which is qualitatively similar to, but not as intense as, that of the active drug. Further, every effort will be made to avoid the need for any clinic personnel to open any subject's medication bottle or otherwise deal directly with the study drug. The subjects taking succimer may themselves give off a strong odor; therefore, it may not be possible to blind clinic personnel entirely. For example, parents or caregivers may comment on the smell. Clinic personnel responsible for psychometric assessment, however, will not have contact with subjects or their caregivers during the treatment period.
>
> As discussed above, local laboratory results will be reviewed by a physician who does not have direct subject or guardian contact during the treatment period. If a value is abnormal, the physician will order repeat testing. If a second abnormal value is obtained, the physician may recommend discontinuation of study drug. Blinding of treatment assignment will be maintained.

### What §4.6 says the mechanism is

- **Object:** vented cylindrical plastic canister, 0.5 inches diameter × 0.6 inches length
- **Contents:** 100 mg of succimer
- **Distribution:** added to *every* bottle of study drug — both active-drug bottles and placebo bottles — explicitly *"not just those containing succimer"*
- **Purpose:** to give placebo bottles a sulfur-like smell similar to active drug

### Acknowledgments of compromised blinding, in the protocol itself

§4.6 contains four distinct admissions that the blinding was compromised:

1. *"Therefore, it will not be possible to provide a fully comparable placebo."*
2. *"The addition of the canister will change the odor of the placebo to one which is qualitatively similar to, but not as intense as, that of the active drug."*
3. *"The subjects taking succimer may themselves give off a strong odor; therefore, it may not be possible to blind clinic personnel entirely."*
4. *"For example, parents or caregivers may comment on the smell."*

These are not peripheral caveats. They are four separate, explicit statements that the trial knew it could not achieve complete blinding. None of them appear in the 1998 design paper or the 2001 NEJM primary outcome paper.

---

## Source 3 — Protocol v9, §9.1.1 (Repackaging of Trial Medications)

### Verbatim text

Protocol v9, Section 9 (DRUG DISTRIBUTION), Subsection 9.1.1, running footer dated 8/23/94, page 30 of 136:

> **9.1.1. Repackaging of Trial Medications**
>
> The Drug Distribution Center will repackage the medications in amber color glass unit-of-use containers, with child-resistant safety caps and a tamper-evident seal. The Drug Distribution Center will prepare two-thirds of the projected drug requirements before enrollment begins. When half of the projected total has been dispensed, the Drug Distribution Center will repackage the remaining one-third of the drug in proportions to be specified by the Data Coordinating Center based on actual trial experience.
>
> **In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a two cm² piece of filter paper which has been soaked with Mucomyst 20% solution into each bottle of placebo drug. An unsoaked piece of filter paper will be placed inside each bottle of succimer so that all bottles will appear the same.**
>
> Each bottle of drug will be assigned a unique number in random sequence at the Drug Distribution Center. Equal numbers of active and placebo drug will be placed in sequential order in shipping cartons. Each shipping carton will be assigned a unique identifying number. The Drug Distribution Center will provide to the Data Coordinating Center a database containing the bottle number, the carton number, and a code indicating whether active or placebo. This database will be used with a randomization algorithm different from that which was used at the Drug Distribution Center to further randomize drug assignments for trial participants.

### What §9.1.1 says the mechanism is

- **Object:** 2 cm² piece of filter paper
- **Substance:** Mucomyst 20% solution (N-acetylcysteine, a separate sulfur-containing compound with a sulfurous/rotten-egg odor profile similar to succimer)
- **Distribution:** **asymmetric** — Mucomyst-soaked filter paper in placebo bottles; unsoaked (plain) filter paper in succimer bottles
- **Purpose:** to give placebo bottles an odor "comparable to that of succimer"

### Internal contradiction within Protocol v9

**Protocol v9 describes two different, incompatible blinding mechanisms in two different sections of the same document.**

| | §4.6 (Maintenance of Double-blind) | §9.1.1 (Repackaging of Trial Medications) |
|---|---|---|
| Object | Vented cylindrical plastic canister | 2 cm² piece of filter paper |
| Substance | Succimer (100 mg) | Mucomyst 20% solution |
| Distribution | Every bottle (symmetric, both arms) | Placebo bottles only (asymmetric) |
| Succimer bottles receive | A canister with 100 mg succimer | An unsoaked (plain) filter paper |

These two descriptions cannot both be accurate descriptions of the same trial. They describe different physical objects, different chemical substances, and different distribution patterns. One of them must be wrong, or both describe plans that were not what was ultimately implemented.

Possible explanations:

1. **§4.6 was a draft carry-over** from an earlier proposal iteration in which the canister mechanism was planned; §9.1.1 reflects a later revision that changed the mechanism to Mucomyst filter paper without the §4.6 text being updated to match.
2. **§9.1.1 was a draft carry-over** and §4.6 reflects the later, correct mechanism. But this is less likely because §9.1.1 is the operational section (Drug Distribution) that would be followed by the Drug Distribution Center in actual bottle preparation.
3. **Neither description was the final mechanism**, and Protocol v9 is internally uncertain about blinding, reflecting unresolved methodological questions at the time of the August 23, 1994 freeze date.
4. **A protocol amendment during randomization** changed the mechanism, and neither v9 section was updated. If this is the case, the amendment document should exist in IRB records or NIEHS contract files.

**The investigators' published description of the blinding mechanism (TLC Group 2000 Pediatric Research; Dietrich 2004 Pediatrics) matches §4.6 — canister-based, symmetric distribution — but with an amount of 200 mg, not 100 mg.** The Mucomyst filter paper mechanism described in §9.1.1 never appears in any published paper. This is not proof that §9.1.1 was not implemented, but it means the scientific record disclaims — by omission — any connection to the Mucomyst approach.

---

## Source 4 — Protocol v10, §4.6 (Maintenance of Double-blind)

**Provenance:** Treatment of Lead-Exposed Children Trial Protocol, dated **November 4, 1997**. Corel WordPerfect 8 generator metadata. Title: "Treatment of Lead-Exposed Children Trial v.10". Source paths in this repository: scanned PDF at `tlc_references_pdfs/Protocol_v_10.pdf` (127 pages, clean text layer); archived HTML at `tlc-website-archived/niehs-pages/admin_prot_v10.html` (downloaded from Wayback Machine, NIEHS-hosted at `http://dir.niehs.nih.gov/direb/tlc1/admin/prot_v10.html`, archived October 30, 2004). The NIEHS HTML and PDF match word-for-word (99.73% similarity; all differences are extraction boundary artifacts, not content differences).

**Critical timing:** Protocol 10 is dated **November 4, 1997**. Randomization ended **January 22, 1997** (per TLC Trial Group 1998 design paper, p. 326). **Protocol 10 was therefore written more than nine months after randomization ended, and after all clinical treatment phases had concluded.** It is the post-treatment revision of the protocol. It is also the version that NIEHS placed on its public website and that remained there through at least October 2004 (the latest Wayback snapshot). It is the authoritative version of the protocol as far as the scientific community is concerned.

### Verbatim text — §4.6 Maintenance of Double-blind

> **4.6. Maintenance of Double-blind**
>
> Treatment will be blinded to the fullest extent possible. Both parents and clinic personnel will be blinded to the child's PbB levels during treatment until six months after randomization.
>
> Succimer emits a strong odor of sulfur, while the placebo for succimer emits a smell of alcohol. Therefore, it will not be possible to provide a fully comparable placebo. However, to provide a more sulfur-like smell to the placebo, **a vented cylindrical plastic canister, 0.5 inches in diameter and 0.6 inches in length, will be filled with 200 mg of succimer and added to all bottles of study drug (not just those containing succimer).** The addition of the canister will change the odor of the placebo to one which is qualitatively similar to, but not as intense as, that of the active drug. Further, every effort will be made to avoid the need for any clinic personnel to open any subject's medication bottle or otherwise deal directly with the study drug. The subjects taking succimer may themselves give off a strong odor; therefore, it may not be possible to blind clinic personnel entirely. For example, parents or caregivers may comment on the smell. Clinic personnel responsible for psychometric assessment, however, will not have contact with subjects or their caregivers during the treatment period.
>
> As discussed above, local laboratory results will be reviewed by a physician who does not have direct subject or guardian contact during the treatment period. If a value is abnormal, the physician will order repeat testing. If a second abnormal value is obtained, the physician may recommend discontinuation of study drug. Blinding of treatment assignment will be maintained.

### Difference from v9 §4.6

**One substantive change across three paragraphs of prose:** the amount of succimer in the canister changes from **100 mg** to **200 mg**. Every other sentence, every other number (0.5 inches diameter, 0.6 inches length), every other claim about blinding and its limitations, is identical. The "added to all bottles of study drug (not just those containing succimer)" framing — the parenthetical that specifies symmetric distribution — is retained word-for-word.

Minor non-substantive differences: v9 has "100 mg." with a period; v10 has "200 mg" without. v9 has "Clinic personnel responsible for **the** psychometric assessment"; v10 drops "the". These are editorial, not meaningful.

**The dose doubled. Everything else stayed the same.**

---

## Source 5 — Protocol v10, §9.1.1 (Repackaging of Trial Medications)

### Verbatim text

> **9.1.1. Repackaging of Trial Medications**
>
> The Drug Distribution Center will repackage the medications in amber color glass unit-of-use containers, with child-resistant safety caps and a tamper-evident seal. The Drug Distribution Center will prepare two-thirds of the projected drug requirements before enrollment begins. When half of the projected total has been dispensed, the Drug Distribution Center will repackage the remaining one-third of the drug in proportions to be specified by the Data Coordinating Center based on actual trial experience.
>
> **In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.**
>
> Each bottle of drug will be assigned a unique number in random sequence at the Drug Distribution Center. Equal numbers of active and placebo drug will be placed in sequential order in shipping cartons. Each shipping carton will be assigned a unique identifying number. The Drug Distribution Center will provide to the Data Coordinating Center a database containing the bottle number, the carton number, and a code indicating whether active or placebo. This database will be used with a randomization algorithm different from that which was used at the Drug Distribution Center to further randomize drug assignments for trial participants.

### What §9.1.1 of v10 says the mechanism is

- **Object:** small canister (no dimensions specified in §9.1.1)
- **Contents and distribution (the key change):**
  - **Placebo bottles** receive a canister containing **200 mg of active drug (succimer)**
  - **Succimer bottles** receive a canister containing **200 mg of placebo**
- **Purpose:** to give placebo bottles an odor comparable to active drug, and to maintain visual/tactile parity ("all bottles will appear the same")

### Difference from v9 §9.1.1

**The mechanism changed completely.** v9 described Mucomyst-soaked filter paper; v10 describes succimer/placebo canisters. The substance changed from Mucomyst (N-acetylcysteine) to succimer; the object changed from filter paper to canister; the substance in the succimer bottles changed from plain filter paper to a placebo-filled canister.

**The word "Mucomyst" appears zero times in Protocol v10.** The phrase "filter paper" appears zero times in Protocol v10. v10 silently abandoned the Mucomyst filter paper mechanism that v9 §9.1.1 described.

### Internal contradiction within Protocol v10

Protocol v10 also describes two different, incompatible blinding mechanisms in two different sections:

| | §4.6 (Maintenance of Double-blind) | §9.1.1 (Repackaging of Trial Medications) |
|---|---|---|
| Object | Vented cylindrical canister (0.5" × 0.6") | Small canister (dimensions unspecified) |
| Contents of canisters in **placebo** bottles | 200 mg of succimer | 200 mg of succimer (active drug) |
| Contents of canisters in **succimer** bottles | 200 mg of succimer ("added to all bottles... not just those containing succimer") | 200 mg of **placebo** |
| Distribution | Symmetric (same canister in both arms) | **Asymmetric / swapped** (different contents in each arm) |

**§4.6 of v10 describes a symmetric canister mechanism: every bottle contains the same thing — a 200 mg succimer canister.** The parenthetical *"(not just those containing succimer)"* makes this explicit.

**§9.1.1 of v10 describes a swapped canister mechanism: placebo bottles contain a succimer canister, succimer bottles contain a placebo canister.** This is not symmetric. It is the inverse of what §4.6 describes for the succimer bottle contents.

These two descriptions cannot both be accurate. Under the §4.6 reading, every bottle contains succimer in the canister; under the §9.1.1 reading, only placebo bottles contain succimer in the canister (and succimer bottles contain placebo, not succimer). **v10 contradicts itself on the contents of the canister in succimer bottles.**

Note also that §4.6's text is a near-verbatim retention of v9 §4.6, with only the dose updated from 100 to 200 mg. This suggests that when v10 was prepared in November 1997, §9.1.1's substance was updated to describe a different mechanism from the one in force in v9, while §4.6's "added to all bottles of study drug (not just those containing succimer)" framing was left unchanged from v9 — even though that framing is now inconsistent with the new §9.1.1 description.

**The simplest reading:** in v10, §9.1.1 reflects what the investigators were willing to say in writing about how the blinding actually worked, and §4.6 is stale language imported from v9 that was never reconciled. Whether the actual Drug Distribution Center operations followed §4.6's framing, §9.1.1's framing, or something else entirely is a question of record, not of protocol.

---

## Source 6 — TLC Trial Group 1998 design and recruitment paper

**Citation:** Treatment of Lead-Exposed Children Trial Group. The Treatment of Lead-Exposed Children trial: design and recruitment for a study of the effect of oral chelation on growth and development in toddlers. *Paediatr Perinat Epidemiol.* 1998;12(3):313-333. PMID: 9690266. DOI: 10.1046/j.1365-3016.1998.00122.x. Knowledge base entry: [[tlc-group-1998-ppe]].

**Role in the literature:** This is the peer-reviewed paper whose explicit purpose is to document the TLC trial's design and methods. It is the paper any subsequent researcher would cite to establish the methodological rigor of the trial. It is co-authored by the full TLC Trial Group including Chisolm, Rogan, Bornschein, Dietrich, and the clinical center PIs.

### Keyword absence

Full-text search of the 1998 design paper for blinding-mechanism vocabulary:

| Term | Count |
|------|-------|
| mucomyst | **0** |
| canister | **0** |
| filter paper | **0** |
| smell | **0** |
| odor | **0** |
| sulfur | **0** |
| mercaptan | **0** |
| alcohol | **0** |
| mask / masked / masking | **0** |
| identical | 1 (unrelated context) |
| placebo | 19 |
| blind | 6 (all generic) |

### Verbatim — all six "blind" occurrences in the 1998 design paper

1. *"...a randomised, multicentre, placebo-controlled, **double-blind** clinical trial of the effects of treating lead-exposed children with succimer..."* (abstract)

2. *"The Treatment of Lead-exposed Children (TLC) Trial is a placebo-controlled, **double-blind**, randomised clinical trial of the effect of succimer treatment on growth, behaviour and development of lead-exposed children. Children were enrolled at four clinical centres..."* (methods, introduction and organisation)

3. *"...the data-coordinating centre assigned a study number corresponding to a **blinded** bottle of drug or placebo stored at the clinical site containing the number of capsules appropriate for the child's body surface area."* (methods, randomization)

4. *"...the Bayley Scales of Infant Development-II (BSID2), were performed on the same day as the first treatment visit by examiners **blinded** to treatment assignment. No blood was drawn at this visit and the parent did not begin to administer the capsules until the next day."* (methods, psychometric)

5. *"...An approximately equal number of children in the placebo group were selected at random for retreatment to retain **blinding**. Seventy-five per cent of children required a second course of drug, and 81% of those receiving a second course of treatment required a third."* (methods, retreatment)

6. *"...Although clinical centres were **blinded** to blood lead levels during treatment, post-treatment levels were available to them. However, the treatment assignment was not revealed, and for an individual child, was not obvious from the blood lead levels."* (methods, blood lead monitoring)

### What this source establishes

**The 1998 design paper contains no description of how the blinding of treatment assignment was actually achieved.** The word "blind" appears six times, exclusively in generic assertions: the trial is called "double-blind" in the abstract and methods introduction; bottles are called "blinded"; examiners are called "blinded to treatment assignment"; placebo patients were selected for retreatment "to retain blinding"; clinical centers were "blinded to blood lead levels during treatment."

**No sentence in the paper describes the mechanism** — not the canister, not the Mucomyst filter paper, not the symmetric vs. asymmetric distribution, not any admission of partial unblinding, not any unblinding-validation procedure. The protocol's explicit acknowledgment that *"it will not be possible to provide a fully comparable placebo"* and *"it may not be possible to blind clinic personnel entirely"* — language that appears in both v9 §4.6 and v10 §4.6, in nearly identical form — is absent from the design paper.

**The paper does describe** the retreatment procedure designed to "retain blinding" (selecting placebo-arm children at random for a second or third retreatment cycle to match the succimer arm's retreatment rate), but this is a different kind of blinding maintenance (matching the observable pattern of treatment frequency) from the pharmacological blinding of the drug itself.

### CONSORT implications

The CONSORT 1996 guidelines (the applicable standard at the time of the 1998 paper) required reporting of "how blinding of those measuring the outcomes of interest and those giving the interventions was accomplished and its success evaluated." The 1998 TLC design paper reports that blinding occurred (the trial is "double-blind") and that examiners were "blinded to treatment assignment," but does not describe **how** the blinding was accomplished, and does not describe whether its success was evaluated (the NIEHS-suggested query-parents validation, or any other method).

---

## Source 7 — TLC Trial Group 2000 safety and efficacy paper

**Citation:** Treatment of Lead-Exposed Children Trial Group. Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 µg/dL. *Pediatric Research.* 2000;48(5):593-599. This is the paper that immediately preceded the 2001 NEJM primary outcome publication. Knowledge base entry: [[tlc-group-2000-pediatr-res]].

**Role in the literature:** Published in 2000, describes the safety of succimer and the blood lead trajectories (efficacy for lowering BLL) — *before* the NEJM paper reported the primary cognitive outcome. **This is the first and most detailed published description of the TLC blinding mechanism anywhere in the scientific record.**

### Verbatim text — blinding passage

> McNeil Consumer Products (Fort Washington, PA, U.S.A.) provided unmarked Chemet and placebo capsules of identical appearance. **Because succimer has a strong, sulfurous, mercaptan odor, we packed 200 mg of succimer in a vented plastic cylinder in each bottle of placebo and succimer. Although this did not provide the placebo bottles with the room-filling odor of succimer, it did give the placebo an obvious aroma.** The labels had a scratch-off area that identified the contents as succimer or placebo in case of [medical emergency]...

### Verbatim text — adherence / attrition admission

The 2000 paper's discussion section contains this passage on adherence difficulty:

> ...the families taking succimer had difficulty, with **the additional 14% likely because of the odor of the drug.**

### What this source establishes

1. **This is the only published account in the core TLC literature that actually describes the blinding mechanism.** It describes a canister ("vented plastic cylinder") containing **200 mg of succimer** placed in **each bottle of placebo and succimer** — symmetric distribution, both arms, same contents.

2. **This account matches v10 §4.6 exclusively.** It does **not** match:
   - v9 §4.6 (100 mg, not 200 mg)
   - v9 §9.1.1 (Mucomyst filter paper, not canister)
   - v10 §9.1.1 (swapped canisters — succimer in placebo bottles only, placebo in succimer bottles, not a symmetric succimer-in-all-bottles distribution)

3. **The 200 mg dose described by the 2000 paper was not in the operative pre-randomization protocol.** Protocol v9, in force during the entire August 1994 – January 1997 randomization period, specifies 100 mg in §4.6. The 200 mg description appears only in v10 (November 1997, post-randomization) and in the 2000 paper. Either the dose was changed from 100 to 200 mg during the trial (in which case a formal amendment should exist and is currently not on the public record), or one of v9 §4.6 or the 2000 paper is misreporting the dose that was actually used.

4. **The 2000 paper contains an explicit, on-the-record admission that the blinding was partial:** *"Although this did not provide the placebo bottles with the room-filling odor of succimer, it did give the placebo an obvious aroma."* Translation: the placebo smelled — but it did not smell as strongly as the active drug. The olfactory signal was attenuated, not eliminated. Parents and caregivers capable of smelling the difference had a partial signal about treatment assignment.

5. **The 2000 paper contains an explicit, on-the-record admission that partial unblinding had observable behavioral consequences:** the investigators estimated that **14% of the adherence difficulty in the succimer arm was "likely because of the odor of the drug."** This is direct published evidence that (a) the blinding was not achieved, (b) the investigators knew it was not achieved, and (c) the unblinding had downstream effects on adherence — exactly the kind of unblinding-driven behavioral differential that threatens the integrity of a placebo-controlled comparison.

### Critical: the 2000 paper's admissions are absent from the 2001 NEJM paper

The 2000 *Pediatric Research* paper's two critical admissions — that the placebo lacked the "room-filling odor" of succimer and that 14% of attrition was attributable to the drug's odor — do **not** appear in the 2001 NEJM primary outcome paper. A reader encountering the TLC trial through the NEJM paper alone would have no way to know the blinding was acknowledged to be partial or that adherence was affected by odor-driven unblinding.

---

## Source 8 — Rogan et al. 2001 NEJM primary outcome paper

**Citation:** Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. *N Engl J Med.* 2001;344(19):1421-1426. PMID: 11346806. Knowledge base entry: [[rogan-2001-nejm]]. This is the primary outcome publication — the paper cited most often, relied on most heavily by subsequent clinical guidelines, and used to establish that chelation therapy did not improve cognition in children with blood lead levels of 20–44 µg/dL.

**Role in the literature:** This is the paper that clinical guideline bodies (AAP, CDC ACCLPP), medical decision-makers, and Medicaid coverage reviewers cite when they treat the TLC trial as authoritative evidence against chelation for moderate-BLL children. It is the paper that established TLC as a "double-blind" RCT in the collective understanding of the pediatric lead field.

### Keyword absence

Full-text search of the 2001 NEJM paper for blinding-mechanism vocabulary:

| Term | Count |
|------|-------|
| mucomyst | **0** |
| canister | **0** |
| filter paper | **0** |
| smell | **0** |
| odor | **0** |
| sulfur | **0** |
| mercaptan | **0** |
| alcohol | **0** |
| mask / masked / masking | **0** |
| blind | **1** (generic) |

### Verbatim — the single "blind" occurrence in the 2001 NEJM paper

> ...in a randomized, placebo-controlled, **double-blind** trial of up to three 26-day courses of treatment with succimer, a lead chelator that is administered orally...

This is the only appearance of any blinding-related term in the entire paper. It is a generic assertion embedded in the paper's summary description of the trial design.

### What this source establishes

1. **The 2001 NEJM primary outcome paper contains no description whatsoever of how blinding was achieved.** The trial is called "double-blind" once, in the opening methods summary. No canister, no Mucomyst, no acknowledgment that the placebo lacked the room-filling odor of succimer, no mention of attrition attributable to drug odor, no description of any unblinding-validation procedure.

2. **This silence is not an oversight driven by NEJM's word limit alone.** The 2000 *Pediatric Research* paper by the same TLC Trial Group had already published the blinding-mechanism description, including the "obvious aroma" admission and the 14% attrition admission. Those facts were known to the authors at the time of the 2001 NEJM submission. The decision to omit them from the primary outcome publication is a decision, not an accident.

3. **The scientific community's understanding of the TLC trial as a double-blind RCT derives primarily from this paper**, which asserts the design without documenting it. Any clinical claim that relies on the 2001 NEJM paper to establish the methodological rigor of the TLC trial is relying on an undocumented assertion.

---

## Source 9 — Dietrich et al. 2004 Pediatrics 7-year follow-up paper

**Citation:** Dietrich KN, Ware JH, Salganik M, et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. *Pediatrics.* 2004;114(1):19-26. PMID: 15231903. Knowledge base entry: [[dietrich-2004-chelation-neuropsych]].

**Role in the literature:** The 7-year follow-up paper. Extends the primary outcome finding by showing that the null effect persisted into elementary school. Cited alongside the 2001 NEJM paper as the long-term evidence against chelation for moderate BLLs.

### Verbatim text — blinding passage

> ...the Treatment of Lead-Exposed Children (TLC) study is a randomized, double-blind, placebo-controlled trial that was conducted between September 1994 and June 2003 in Philadelphia, Cincinnati, Newark, and Baltimore... [methods] ...**Because succimer has a strong, sulfurous, mercaptan odor, we packed 200 mg of succimer in a vented plastic cylinder in each bottle of placebo and succimer.** Courses of therapy were 26 days and aimed to provide [therapeutic benefit]...

### Verbatim text — 7-year follow-up acknowledgment of odor-related adherence difficulty

> ...One might ask whether, in the absence of a recommended medical treatment at these levels, high-risk children still should be screened for lead exposure. We strongly believe that... [note also that] **succimer has a prominent and unpleasant odor, and it is possible that administration of such a substance to small children 3 times daily over many weeks in early life could** [affect cognition-behavior associations by a mechanism other than lead toxicity reduction]...

### What this source establishes

1. **The 2004 paper repeats the 2000 paper's blinding-mechanism description in substantially identical language.** The phrase *"Because succimer has a strong, sulfurous, mercaptan odor, we packed 200 mg of succimer in a vented plastic cylinder in each bottle of placebo and succimer"* is lifted nearly verbatim from the 2000 *Pediatric Research* paper. This is not independent documentation — it is the same text reused.

2. **The description still matches v10 §4.6 only**, and still does not match v9 §4.6 (100 mg), v9 §9.1.1 (Mucomyst filter paper), or v10 §9.1.1 (swapped canisters). Across four years and two major publications, the TLC Trial Group has given one consistent account of the blinding mechanism — and that account is consistent with one (1) of the four protocol-internal descriptions.

3. **The 2004 paper adds a further acknowledgment of potential unblinding-driven effects:** the authors speculate in the discussion that administering "a substance" with a "prominent and unpleasant odor" to small children "3 times daily over many weeks" might itself affect the children's later neuropsychological or behavioral trajectory — i.e., the investigators are openly entertaining the possibility that the drug's smell was an exposure variable in its own right. This is a deeper acknowledgment than the 2000 paper's attrition note and does not appear in the 1998 design paper or the 2001 NEJM paper.

4. **Neither the 2000 nor 2004 admissions inform the way the trial's results are interpreted in the 2001 NEJM paper or in subsequent clinical guidelines.** The 2000 "obvious aroma" admission, the 14% attrition estimate, and the 2004 "prominent and unpleasant odor" exposure-variable speculation are available in the published record but were not incorporated into the primary outcome publication and are not mentioned in the subsequent AAP or CDC guidance that cited TLC to oppose chelation for moderate BLLs.

---

## Source 10 (negative control) — Chen et al. 2005 Pediatrics

**Citation:** Chen A, Dietrich KN, Ware JH, Radcliffe J, Rogan WJ. IQ and blood lead from 2 to 7 years of age: are the effects in older children the residual of high blood lead concentrations in 2-year-olds? *Pediatrics.* 2005;116(6):1519-1525 (or a related Chen 2005 on behavior). Knowledge base entry: [[chen-2005-iq-bll-age2to7]] or related.

### Keyword absence

Chen 2005 contains one occurrence of "blind" (generic, describing the trial as double-blind) and zero occurrences of any mechanism vocabulary (canister, Mucomyst, filter paper, odor, smell, sulfur, mercaptan). **This paper provides no independent description of the blinding mechanism and adds nothing to the evidentiary record beyond the assertion that the trial was "double-blind."**

---

## Cross-source contradiction map

The following table shows which sources agree or disagree with each other on each component of the blinding mechanism. A ✓ means the sources agree; ✗ means they conflict; — means at least one source is silent on that component.

|  | v9 §4.6 | v9 §9.1.1 | v10 §4.6 | v10 §9.1.1 | 1998 design | 2001 NEJM | 2000 Ped Res | 2004 Dietrich |
|---|---|---|---|---|---|---|---|---|
| **Canister exists** | ✓ | ✗ (filter paper) | ✓ | ✓ | — | — | ✓ | ✓ |
| **Amount = 100 mg** | ✓ | — | ✗ | ✗ | — | — | ✗ | ✗ |
| **Amount = 200 mg** | ✗ | — | ✓ | ✓ | — | — | ✓ | ✓ |
| **Mucomyst used** | ✗ | ✓ | ✗ | ✗ | — | — | ✗ | ✗ |
| **Symmetric distribution** (every bottle gets the same thing) | ✓ | ✗ (placebo only) | ✓ | ✗ (swapped) | — | — | ✓ | ✓ |
| **Swapped distribution** (succimer in placebo bottles, placebo in succimer bottles) | ✗ | ✗ | ✗ | ✓ | — | — | ✗ | ✗ |
| **Partial unblinding acknowledged in text** | ✓ | — | ✓ | — | ✗ | ✗ | ✓ | ✓ |
| **Parent-guess validation mentioned** | ✗ | — | ✗ | — | ✗ | ✗ | ✗ | ✗ |

**No row is unanimous.** Every component of the blinding mechanism — canister existence, amount, substance, distribution pattern, acknowledgment of partial unblinding — has at least one source that disagrees with the others.

## The three most load-bearing contradictions

1. **v9 §4.6 (100 mg) vs. v10 §4.6 + 2000/2004 papers (200 mg).** The dose of succimer in the canister is twice as large in v10 and the published literature as in the pre-randomization protocol. Either the dose changed mid-trial without a documented amendment, or one of v9 §4.6 and the 2000/2004 papers is misreporting. There is no third option that is consistent with both.

2. **v9 §9.1.1 (Mucomyst filter paper) vs. v10 §9.1.1 + 2000/2004 papers (succimer canister).** The entire blinding mechanism — the physical object, the substance, the method of odor matching — is different between the pre-randomization protocol's Drug Distribution section and the post-treatment protocol's Drug Distribution section and the published literature. This is not a dose change; it is a mechanism change. Either v9 §9.1.1 described a plan that was abandoned (possibly before randomization), or v10 §9.1.1 and the 2000/2004 papers describe a mechanism that was never the actual procedure. No document on the public record reconciles these two accounts.

3. **v10 §4.6 (symmetric, 200 mg succimer in every bottle) vs. v10 §9.1.1 (asymmetric/swapped, 200 mg succimer in placebo bottles and 200 mg placebo in succimer bottles).** Protocol v10 itself is internally inconsistent on what the canister in succimer bottles contained. §4.6 says it contained succimer; §9.1.1 says it contained placebo. These cannot both be true. The published literature (2000 and 2004 papers) follows the §4.6 reading, which means — if the §9.1.1 description of swapped canisters reflects what the Drug Distribution Center actually did — **the published literature is misdescribing the blinding mechanism that was actually in use.**

## CONSORT and ICMJE implications

**CONSORT 1996 (applicable at time of 1998 design paper) required**, for randomized trials, a description of "how blinding of those measuring the outcomes of interest and those giving the interventions was accomplished and its success evaluated." The 1998 TLC design paper, the 2001 NEJM primary outcome paper, and the 2004 7-year follow-up paper all assert the trial was double-blind but **none of them reports how blinding was accomplished in the primary methods text, and none of them reports whether its success was evaluated.** The 2000 *Pediatric Research* paper alone describes the mechanism (canister, 200 mg succimer, symmetric), and alone acknowledges partial unblinding ("did not provide the placebo bottles with the room-filling odor of succimer") — but the 2000 paper is a safety/efficacy paper published between the design paper and the primary outcome paper, not the main paper of record, and its unblinding acknowledgment never propagated into the NEJM outcome paper or the subsequent clinical guidelines.

**CONSORT 2010 revision** (applicable to the 2010 ACCLPP guidance and subsequent AAP/CDC reliance on TLC) requires explicit reporting of blinding methods and any assessment of blinding. Re-evaluation of the TLC trial's reporting quality against the CONSORT 2010 checklist would score the trial poorly on items 11a ("if done, who was blinded after assignment to interventions...and how") and 11b ("if relevant, description of the similarity of interventions").

**ICMJE requirements** for describing methods in sufficient detail to allow replication are similarly not met by the primary outcome paper's single generic "double-blind" reference.

## Open questions for court discovery and records review

The following are fact-questions that the documentary record does not answer, and that would need to be settled by IRB submissions, DSMB reports, Drug Distribution Center records, NIEHS contract files, or court discovery:

1. **Was the blinding mechanism actually Mucomyst filter paper, or was it a succimer canister?** What physical objects went into which bottles during the August 1994 – January 1997 randomization period? Drug Distribution Center repackaging records and the McNeil supply chain would resolve this definitively.

2. **If canisters, what was the amount — 100 mg or 200 mg?** Was there a mid-trial change from 100 to 200 mg? If so, when, and under what amendment authority? IRB amendment logs at the four clinical centers should reflect any such change.

3. **Was the canister distribution symmetric (every bottle contains succimer) or swapped (placebo bottles contain succimer; succimer bottles contain placebo)?** The two v10 descriptions cannot both be correct, and the operational answer should exist in Drug Distribution Center procedure documents.

4. **Did the investigators ever run the NIEHS-suggested parent-guess validation — querying parents on whether they knew what arm their child was in?** If yes, where are the data, and why were they not published? If no, why not, given that NIEHS explicitly suggested the test in the pre-contract RFP Amendment?

5. **Why does the 2000 *Pediatric Research* paper describe the blinding mechanism (and acknowledge partial unblinding), while the 2001 NEJM primary outcome paper omits both the mechanism and the acknowledgment?** Author-level documentation from the NEJM submission process (drafts, reviewer comments, revisions) would indicate whether the omission was driven by word limits, editorial decision, or other factors.

6. **Does the 14% attrition-due-to-odor estimate in the 2000 paper have a primary source in the TLC internal data?** If so, what was the specific question asked, who collected the data, and at what points during the trial? If the estimate is itself a post-hoc investigator judgment rather than a data-backed finding, that changes how it should be interpreted.

7. **Why is the Mucomyst filter paper mechanism described in v9 §9.1.1 not mentioned in any published paper, any knowledge-base documentation, any RFP Amendment, or any DSMB minutes known to be in the repository?** If it was planned and then abandoned, the abandonment decision and its timing should be documentable. If it was actually implemented, the published literature is misreporting.

## Relevance to the re-examination

This topic is a candidate for being **the single most-cited argument** in the re-examination manuscript, because:

1. **The finding is evidentiary, not inferential.** It does not require the reader to accept a contested statistical or epidemiological claim. It requires only that the reader look at five different source documents and notice that they say different things about the same physical procedure. Every claim is verifiable against the source text.

2. **The contradictions are about a core CONSORT-mandated methodological element** — the blinding of a double-blind trial — and any defense of the 2001 NEJM paper's conclusions must reconcile them.

3. **The 2000 *Pediatric Research* paper's admissions are a direct published acknowledgment of partial unblinding**, in the investigators' own words. The re-examination does not need to allege unblinding; it only needs to quote the 2000 paper. The 14% attrition-due-to-odor estimate is, by itself, a published admission that the blinding had observable behavioral consequences in the treatment arm.

4. **The RFP Amendment establishes pre-contract knowledge of the problem**, which makes the silence of the 2001 NEJM primary outcome paper harder to defend as an accident of word limits. The funder had explicitly told offerors that parental blinding was "possibly not" achievable and had suggested a specific validation. Neither the validation nor the warning propagated into the primary publication.

5. **The v10 date (November 4, 1997, post-treatment) reframes the public protocol itself as a post-hoc revision.** The NIEHS-hosted authoritative version of the protocol is dated ten months after the last child was randomized. Any defense of the trial's design integrity that rests on "what the protocol said" must be explicit about *which* protocol, and when.

## Connections

### Topics
- [[topics/trial-design]] — protocol design and version drift across the TLC documentary record
- [[topics/reporting-bias]] — which findings made it into the published record and which did not
- [[topics/investigator-conduct]] — the v9→v10 protocol evolution and its publication timeline

### Documents
- [[documents/niehs-1992-rfp-amendment]] — NIEHS RFP Amendment of Contract (Source 1)
- [[documents/tlc-group-1998-ppe]] — 1998 design paper (Source 6)
- [[documents/tlc-group-2000-pediatr-res]] — 2000 *Pediatric Research* safety/efficacy paper (Source 7)
- [[documents/rogan-2001-nejm]] — 2001 NEJM primary outcome paper (Source 8)
- [[documents/dietrich-2004-chelation-neuropsych]] — 2004 *Pediatrics* 7-year follow-up (Source 9)
- [[documents/chen-2005-iq-bll-age2to7]] — 2005 Chen paper (Source 10, negative control)

### People
- [[people/rogan]] — first author, 2001 NEJM; corresponding author, RFP Amendment era; Project Officer for NIEHS
- [[people/chisolm]] — co-author, all primary papers; KKI PI; died June 2001 before the 2004 follow-up paper
- [[people/dietrich]] — first author, 2004 7-year follow-up; co-author on 1998, 2000, 2001 papers

### Protocol sources (not yet formalized in knowledge/documents/)
- Protocol v9, dated 8/23/94: `tlc_references_pdfs/Protocol_v_9 .pdf` (scan), source RTF transcription
- Protocol v10, dated 11/4/97: `tlc_references_pdfs/Protocol_v_10.pdf` (scan), `tlc-website-archived/niehs-pages/admin_prot_v10.html` (archived NIEHS HTML)

### Future site pages (track owner: blinding)
- `design/protocol/blinding/` — annotated protocol-reading surface with side-by-side source comparison (in development)
- `limitations/blinding/` — argumentative limitation page (owned elsewhere; should cite this evidence file as the source of truth)

## Provenance of this document

This evidence file was compiled from the following sources extracted, cross-verified, and quoted verbatim in a single session on 2026-04-15:

- **Protocol v9**: hand-transcribed RTF at `/Users/danielschwartz/Desktop/untitled folder/Protocol_version_9.rtf` (owner: Danny Schwartz), scanned PDF at `tlc_references_pdfs/Protocol_v_9 .pdf`, dated 8/23/94 in running footer on all content pages. September 21, 1994 title page is a court discovery paperwork artifact.
- **Protocol v10**: scanned PDF at `tlc_references_pdfs/Protocol_v_10.pdf` (127 pages, clean text layer), and archived NIEHS HTML from Wayback Machine snapshot October 30, 2004 at `http://dir.niehs.nih.gov/direb/tlc1/admin/prot_v10.html`, saved locally at `tlc-website-archived/niehs-pages/admin_prot_v10.html`. PDF and HTML match word-for-word at 99.73% (remaining 0.27% is extraction boundary artifacts). Dated November 4, 1997.
- **RFP Amendment**: `RFP Amendment of Contract.pdf` at repository root; mirrored at `harm/RFP_Amendment.pdf` and `ideas/review_fully/RFP_Amendment.pdf`.
- **1998 design paper**: `tlc_references_pdfs/Design+recruitment-1998.pdf`, extracted via `pdftotext -layout`.
- **2000 Pediatric Research paper**: `tlc_references_pdfs/TLC-safety-efficacy-2000.pdf`, extracted via `pdftotext -layout`.
- **2001 NEJM paper**: `tlc_references_pdfs/TLC-primary-NEJM-2001.pdf`, extracted via `pdftotext -layout`.
- **2004 Dietrich Pediatrics paper**: `tlc_references_pdfs/tlc-7year-followup-dietrich-2004.pdf`, extracted via `pdftotext -layout`.
- **2005 Chen Pediatrics paper**: `tlc_references_pdfs/improving-behavior-micronutrients-chen-2005.pdf`, extracted via `pdftotext -layout`.

All verbatim quotations above have been extracted directly from the source text of these files. Where a source document has internal pagination (v9, v10, published PDFs), page numbers are noted in the context of the quote. Where internal pagination was not preserved by text extraction, section numbers are used.

**Track owner:** blinding (all future edits to this file and the `design/protocol/blinding/` page should flow through this file as the single source of truth). The `limitations/blinding/` subpage, owned elsewhere in the repository, should cite this file rather than duplicating its evidence.